Valuation: StemCells Inc

Market Cap 116M 100M 93.47M 85.82M 162M 11.03B 165M 1.1B 432M 5.49B 434M 424M 18.41B P/E 2026 *
-6.14x
P/E 2027 * -5.8x
Enterprise Value 116M 100M 93.47M 85.82M 162M 11.03B 165M 1.1B 432M 5.49B 434M 424M 18.41B EV / Sales 2026 *
33.5x
EV / Sales 2027 * 10.9x
Free-Float
100%
Yield 2026 *
-
Yield 2027 * -
24/06 Microbot Medical Announces First Health System in Pennsylvania to Adopt the Liberty Endovascular Robotic System CI
17/06 Microbot Medical Inc. Enters Into Agreement With Lovell Government Services To Expand Access For America?s Veteran And Military Patient Populations CI
16/06 Microbot Medical Enters Agreement Expanding Access to Federal Healthcare Systems MT
09/06 Microbot Medical Inc. Announces A Notable Health System as the First in Michigan to Adopt the Liberty Endovascular Robotic System CI
03/06 Microbot Medical Inc. Secures First North Carolina Healthcare System to Adopt the LIBERTY Endovascular Robotic System CI
27/05 Microbot Medical Inc. Receives Its First International Regulatory Approval for the Commercialization of the LIBERTY Endovascular Robotic System CI
19/05 Microbot Medical Inc. - Shareholder/Analyst Call
14/05 Microbot Medical recorded revenue during its quarter ended March 31, benefiting from limited market release of Liberty System RE
14/05 Microbot Medical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05/05 Microbot Medical®'s Liberty® endovascular robotic system is now adopted by multiple accounts across key territories including two Access-PVI pivotal clinical trial sites RE
05/05 Microbot Medical Inc Wins Accounts for Liberty Endovascular Robotic System Across Key Territories CI
14/04 Microbot Medical Inc. Commences Full Market Release Of Liberty Endovascular Robotic System In The U.S CI
27/03 Microbot Medical Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
Manager TitleAgeSince
Chief Executive Officer 54 02/08/1988
Director of Finance/CFO 47 01/04/2022
Chief Operating Officer - 21/01/2025
Director TitleAgeSince
Chairman 54 01/01/2013
Director/Board Member 61 28/11/2016
Director/Board Member 65 06/02/2017
Change 5-day change 1-year change 3-year change Capi.($)
-1.40%+2.59%-1.71%+11.28% 48.53B
-2.41%-0.90%+411.96%+495.33% 39.87B
-1.16%+12.96%+28.81%+7.25% 38.68B
-1.88%-3.03%+5.69%+53.00% 35.13B
-1.74%+5.12%+14.44%+41.77% 29.79B
-0.21%-4.04%+36.40%+125.75% 16.11B
-2.85%-3.92% - - 16.08B
-0.64%+2.65%+3.40%+13.11% 13.61B
-1.19%-1.32%-1.73%-34.37% 12.62B
Average -1.50%+1.05%+62.16%+89.14% 27.82B
Weighted average by Cap. -1.60%+2.03%+79.78%+108.61%

Financials

2026 *2027 *
Net sales 3.45M 3M 2.79M 2.56M 4.84M 329M 4.91M 32.9M 12.91M 164M 12.96M 12.67M 550M 10.6M 9.21M 8.58M 7.87M 14.87M 1.01B 15.1M 101M 39.68M 504M 39.81M 38.93M 1.69B
Net income -18.93M -16.45M -15.32M -14.06M -26.55M -1.81B -26.97M -181M -70.85M -900M -71.09M -69.53M -3.02B -20.02M -17.4M -16.2M -14.87M -28.08M -1.91B -28.52M -191M -74.93M -951M -75.17M -73.52M -3.19B
Net Debt - -
Logo StemCells Inc
Microbot Medical Inc. is a pre-commercial stage medical technology company. It has developed the single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems. It specializes in the research, design and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, it is developing a fully disposable robot for various endovascular interventional procedures. The LIBERTY Endovascular Robotic Surgical System is designed to maneuver guidewires and over-the-wire devices (such as microcatheters) within the body’s vasculature. It eliminates the need for extensive capital equipment requiring dedicated Cath-lab rooms as well as dedicated staff. Its addressable markets for the LIBERTY Endovascular Robotic Surgical System include the peripheral interventional radiology, interventional cardiology and interventional neuroradiology markets.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-